FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Ocean Biomedical, Inc. Stock AnalysisComprehensive stock analysis for Ocean Biomedical, Inc. (OCEA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisOCEA
OCEA
Ocean Biomedical, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OCEA
Home🔹Stocks🔹Ocean Biomedical, Inc.

Ocean Biomedical, Inc.

FRC Coverage
OCEA•NASDAQ

Ocean Biomedical, Inc.

FRC Coverage
OCEA•NASDAQ
Sentiment

Your view on OCEA

Sentiment
Your view
OCEA
Ocean Biomedical, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
OCEA
Company Overview

Overview

What the company does, where it operates, and who runs it.

*Ocean Biomedical, Inc. has paid FRC a fee for research coverage and distribution of reports.

About Ocean Biomedical, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Chirinjeev Kathuria
Headquarters
Room 325, 55 Claverick Street, Providence, RI, US
Industry
Biotechnology
Sector
Healthcare
CEO
Chirinjeev Kathuria
Headquarters
Room 325, 55 Claverick Street, Providence, RI, US
Description

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Infographics

Visual summary of the business at a glance.

FRC Research

Research Reports

FRC analyst coverage and recommendations.

Past Reports

Historical coverage archive.

Analyst Notes

Ongoing commentary and updates from FRC analysts.

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News